HC Wainwright Reaffirms "Buy" Rating for Altimmune (NASDAQ:ALT)

Key Points

• HC Wainwright has reiterated a "buy" rating for Altimmune (NASDAQ:ALT) with a price target of $12.00, indicating a potential upside of 212.91% from its previous close.
• Despite some analysts lowering their price targets, Altimmune maintains a consensus rating of "Moderate Buy" with an average target price of $17.40.
• In its last earnings report, Altimmune reported a loss of ($0.27) EPS, beating analyst estimates, with generated revenue of $0.01 million.

HC Wainwright restated their buy rating on shares of Altimmune (NASDAQ:ALT - Free Report) in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a $12.00 price target on the stock. HC Wainwright also issued estimates for Altimmune's Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.06) EPS, Q1 2026 earnings at ($0.31) EPS, Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.25) EPS, FY2027 earnings at ($1.27) EPS, FY2028 earnings at ($0.09) EPS and FY2029 earnings at $1.27 EPS.

A number of other equities analysts also recently commented on the company. B. Riley dropped their price objective on Altimmune from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Wednesday, August 13th. JMP Securities dropped their price objective on Altimmune from $25.00 to $15.00 and set a "market outperform" rating on the stock in a report on Thursday, July 10th. The Goldman Sachs Group upgraded Altimmune to a "strong sell" rating in a report on Thursday, July 10th. Wall Street Zen upgraded Altimmune from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Finally, William Blair restated a "market perform" rating on shares of Altimmune in a report on Friday, June 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $17.40.

Altimmune Price Performance

ALT traded down $0.07 on Wednesday, reaching $3.56. The company had a trading volume of 2,912,059 shares, compared to its average volume of 3,775,136. The company has a fifty day moving average of $4.75 and a 200-day moving average of $5.26. The company has a market capitalization of $314.21 million, a P/E ratio of -3.02 and a beta of -0.01. The company has a current ratio of 20.44, a quick ratio of 20.44 and a debt-to-equity ratio of 0.09. Altimmune has a one year low of $2.90 and a one year high of $11.16.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.05. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. As a group, equities research analysts anticipate that Altimmune will post -1.35 earnings per share for the current year.

Hedge Funds Weigh In On Altimmune

Several institutional investors have recently modified their holdings of the stock. Ameriprise Financial Inc. increased its position in shares of Altimmune by 35.6% during the 4th quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company's stock worth $37,888,000 after purchasing an additional 1,378,854 shares during the last quarter. Federated Hermes Inc. increased its holdings in shares of Altimmune by 387.7% during the 2nd quarter. Federated Hermes Inc. now owns 915,458 shares of the company's stock worth $3,543,000 after acquiring an additional 727,731 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Altimmune by 155.2% during the 2nd quarter. Bank of America Corp DE now owns 716,019 shares of the company's stock worth $2,771,000 after acquiring an additional 435,467 shares during the last quarter. RFG Advisory LLC acquired a new position in shares of Altimmune during the 1st quarter worth approximately $1,622,000. Finally, Nuveen LLC acquired a new position in shares of Altimmune during the 1st quarter worth approximately $1,304,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.